Y-Intercept (HK)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Y-Intercept (HK)’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-32,740	Closed	-$38K	–	2122
2025 Q2	$38K	Buy	+32,740	New	+$43.2K	﹤0.01%	1570
2024 Q4	–	Sell	-12,303	Closed	-$45.3K	–	1736
2024 Q3	$45.3K	Sell	12,303 -91,613	-88%	-$333K	﹤0.01%	1228
2024 Q2	$425K	Buy	+103,916	New	+$1.16M	0.02%	891

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Y-Intercept (HK)'s ZNTL Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 32,740 shares — an estimated $38K sold.

Y-Intercept (HK) first reported a position in ZNTL in Q2 2024 and held it in 3 quarters. The position peaked at $425K in Q2 2024. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Y-Intercept (HK) reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 32,740 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $38K.
Y-Intercept (HK) first reported a position in Zentalis Pharmaceuticals in Q2 2024 and held it in 3 quarters.
Y-Intercept (HK)'s Zentalis Pharmaceuticals position peaked at $425K in Q2 2024.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.